Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma

Ítems similars

• Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
  per: Jessie Zhao, et al.
  Publicat: (2024-11-01)
• Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  per: Nicholas Bingham, et al.
  Publicat: (2025-01-01)
• A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia
  per: Anna Kalff, et al.
  Publicat: (2015-02-01)
• The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma
  per: Tiffany Khong, et al.
  Publicat: (2008-06-01)
• Longitudinal genetically detectable minimal residual disease by fluorescence hybridization confers a poor prognosis in myeloma
  per: Jian Cui, et al.
  Publicat: (2024-01-01)